Evidence map›Paper›PMID 40951081›Full record

ArticleCureus2025

Adjuvant Nivolumab Therapy for Upper Tract Urothelial Carcinoma: A Single-Institution Study.

Akinori Minato, Katsuyoshi Higashijima, Yui Mizushima, Yoshihiro Sugita, Kazumasa Jojima, Rieko Kimuro, Yujiro Nagata, Ikko Tomisaki, Eiji Kashiwagi, Naohiro Fujimoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Akinori MinatoDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Katsuyoshi HigashijimaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Yui MizushimaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Yoshihiro SugitaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Kazumasa JojimaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Rieko KimuroDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Yujiro NagataDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Ikko TomisakiDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Eiji KashiwagiDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Naohiro FujimotoDepartment of Urology, Kurate Hospital, Kurate, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile immune checkpoint inhibitors have transformed adjuvant therapy for urothelial carcinoma, data focused on upper tract urothelial carcinoma (UTUC) remain scarce. In the CheckMate 274 trial, the UTUC subgroup did not demonstrate a definitive survival benefit. This study aimed to evaluate the clinical outcomes of adjuvant nivolumab in patients with high-risk UTUC. PATIENTS AND

methodsOf the 41 patients who underwent radical nephroureterectomy for UTUC at our institution between April 2022 and April 2024, 11 received adjuvant nivolumab, thereby retrospectively analyzed. Their treatment adherence and immune-related adverse events (irAEs) and survival outcomes were assessed.

resultsOf the 11 patients, eight patients (72.7%) received neoadjuvant chemotherapy. Seven (63.6%) completed the 12-month nivolumab regimen. Four discontinued the treatment because of irAEs (n = 2) and disease recurrence (n = 2). None experienced treatment-related death. The one- and two-year metastasis-free survival rates were 81.8% and 70.1%, respectively, with a median of 30 months. The two-year disease-free and overall survival rates were 40.9% and 79.5%, respectively.

conclusionThis is one of the first real-world experiences focused exclusively on patients receiving adjuvant nivolumab for UTUC. The observed delay in distant progression may reflect the systemic therapeutic activity of immune checkpoint blockade in this setting.

Indexed as

adjuvant chemotherapyadjuvant immunotherapyadjuvant nivolumabimmune checkpoint inhibitormuscle-invasive urothelial carcinomaneoadjuvant chemotherapyradical nephroureterectomyupper tract urothelial carcinoma

Identifiers

PMID40951081
PMCPMC12424828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.